A Titanium (IV)-Dithiophenolate Complex and Its Chitosan Nanocomposite: Their Roles towards Rat Liver Injuries In Vivo and against Human Liver Cancer Cell Lines

Titanium (IV)-dithiophenolate complex chitosan nanocomposites (DBT-CSNPs) are featured by their antibacterial activities, cytotoxicity, and capacity to bind with DNA helixes. In this study, their therapeutic effects against rat liver damage induced by carbon tetrachloride (CCl4) and their anti-proliferative activity against human liver cancer (HepG2) cell lines were determined. Results of treatment were compared with cisplatin treatment. Markers of apoptosis, oxidative stress, liver functions, and liver histopathology were determined. The results showed that DBT-CSNPs and DBT treatments abolished liver damage induced by CCl4 and improved liver architecture and functions. DNA fragmentation, Bax, and caspase-8 were reduced, but Bcl-2 and the Bcl-2/Bax ratios were increased. However, there was a non-significant change in the oxidative stress markers. DBT-CSNPs and DBT inhibited the proliferation of HepG2 cells by arresting cells in the G2/M phase and inducing cell death. DBT-CSNPs were more efficient than DBT. Low doses of DBT and DBT-CSNPs applied to healthy rats for 14 days had no adverse effect. DBT and DBT-CSNP treatment gave preferable results than the treatment with cisplatin. In conclusion, DBT-CSNPs and DBT have anti-apoptotic activities against liver injuries and have anti-neoplastic impacts. DBT-CSNPs are more efficient. Both compounds can be used in pharmacological fields.

Automated summary

Titanium (IV)-dithiophenolate complex chitosan nanocomposites (DBT-CSNPs) exhibit antibacterial activities, cytotoxicity, and the ability to bind with DNA helixes. In this study, their therapeutic effects against rat liver damage induced by carbon tetrachloride (CCl4) and their anti-proliferative activity against human liver cancer (HepG2) cell lines were investigated. Results showed that DBT-CSNPs and DBT effectively treated liver damage and inhibited HepG2 cell proliferation, with DBT-CSNPs showing greater efficiency. Both compounds had no adverse effects on healthy rats and outperformed cisplatin in treatment outcomes.